以上内容来自Benzinga Earnings专栏,原文如下:
Madrigal Pharmaceuticals (NASDAQ:MDGL) reported quarterly losses of $(2.71) per share which beat the analyst consensus estimate of $(4.16) by 34.86 percent. This is a 52.29 percent increase over losses of $(5.68) per share from the same period last year. The company reported quarterly sales of $103.22 million which beat the analyst consensus estimate of $98.56 million by 4.73 percent.
精彩评论